Rewalk Robotics Ltd
ReWalk Robotics Ltd (LFWD) develops wearable robotic exoskeletons intended to help people with lower-limb disabilities stand and walk. Investors should know this is a specialist medical‑technology company focused on rehabilitation and mobility solutions; its niche product set relies on clinical acceptance, regulatory clearances, reimbursement policies and adoption by clinics and individuals. With a market capitalisation of about $10.68M, it is a micro‑cap and may be subject to high share‑price volatility and limited liquidity. Revenue growth can hinge on regulatory approvals, partnerships, and sales execution, while R&D and commercialisation costs can weigh on profitability. For long‑term investors, key considerations include product efficacy data, regulatory and reimbursement developments, management execution, cash runway and funding needs. This summary is educational, not personal financial advice — values can rise or fall and past performance is not a reliable guide to future returns. Consider your risk tolerance and seek independent financial advice before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Rewalk Robotics' stock with a target price of $13, indicating strong potential for growth.
Financial Health
Rewalk Robotics is generating decent revenue and cash flow, but its profitability is somewhat limited.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring LFWD
Immersive Rehab & VR Therapy
Virtual and augmented reality are transforming healthcare with innovative digital treatments for physical and psychological healing. These carefully selected companies are at the forefront of creating immersive technologies that offer effective alternatives to traditional therapies, poised to benefit from growing clinical acceptance.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Medical innovation focus
Works on wearable exoskeletons that could change mobility care; regulatory and clinical acceptance are crucial, and outcomes can affect prospects.
Micro‑cap dynamics
With a market cap near $10.7M the stock can be volatile and less liquid — potential for upside but higher risk and price swings are possible.
Market access matters
Growth depends on approvals, reimbursement and partnerships across regions; commercial execution is as important as the technology itself.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
